Form 4: Corcept Therapeutics CEO Sells Over 39,000 Shares Under Pre-Arranged Trading Plan

Joseph K. Belanoff, CEO and Director of Corcept Therapeutics Inc., sold 39,000 shares of common stock on June 2, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Joseph K. Belanoff, the Chief Executive Officer and a Director of Corcept Therapeutics Inc. (CORT), executed multiple sales of common stock on June 2, 2025.
• A total of 39,000 shares of Corcept Therapeutics common stock were disposed of across eight separate transactions.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Belanoff on November 26, 2024.
• The shares were sold at weighted average prices ranging from $78.4211 to $85.0116 per share.
• Following these transactions, Mr. Belanoff's indirect beneficial ownership, held through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, stands at 2,901,985 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's a significant insider sale, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates negative interpretations, suggesting a planned financial management decision rather than a reaction to adverse company developments.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale for diversification or liquidity rather than a reaction to new, negative information.

Negatives

• The sale represents a significant disposition of shares by a key executive, potentially signaling a reduction in direct exposure to the company's stock by its CEO.

Risks

• While executed under a 10b5-1 plan, a large insider sale by the CEO could be perceived negatively by investors, potentially leading to short-term downward pressure on the stock price.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. It reflects an individual executive's portfolio management rather than a company-wide strategic move.

Related Party Transactions

• The transactions involve the sale of common stock by Joseph K. Belanoff, the CEO and a Director, making it a related party transaction. The shares were held indirectly through a revocable living trust.

Stakeholder Impact

• Shareholders may interpret the CEO's sale of a significant number of shares as a signal, although the 10b5-1 plan context suggests it's a pre-planned event rather than a reactive one.
• The sale does not directly impact employees, customers, suppliers, or creditors as it pertains to personal stock holdings of an executive.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, Joseph K. Belanoff, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Pharmaceuticals, Biotechnology